Thursday, September 25
MTE Sessions
18:30 Welcome Reception
Friday, September 26
08:15-08:30 Good Morning Coffee
08:30-08:45 Welcome Note
Congress Co-Chairs
08:45-10:15 Session 1
Controversy: Is survival prolonged if we used CAR-T in second line rather than third-line treatment?
Moderator:
08:45-09:00 Yes: Anna Sureda, Spain
09:00-09:15 No:
Controversy: Is Flu/Cy still the best lymphodepleting regimen?
Moderator: Anna Sureda, Spain
09:15-09:30 Yes:
09:30-09:45 No:
09:45-10:15 Panel discussion: All session faculty
10:15-10:35 Coffee Break, Poster Viewing and Visit Exhibition
10:35-12:05 Session 2
Controversy: Shall we include venetoclax in the induction chemotherapy and/or conditioning regimen before the transplant?
Moderator: TBA
10:35-10:50 Yes: Thomas Schroeder, Germany
10:50-11:05 No: Jurjen Versluis, Netherlands
Controversy: Should we transplant TP53 multi-hit AML or MDS?
Moderator: Mutlu Arat, Turkey
11:05-11:20 Yes: Coleman Lindsley, USA
11:20-11:35 No: Avichai Shimoni, Israel
11:35-12:05 Panel discussion: All session faculty
12:05-12:15 Technical Break
12:15-13:15 Session 3
How to treat PTLD post allograft refractory to anti CD20 therapy?
12:15-12:30 By EBV specific T cells:
12:30-12:45 By CAR T cells:
12:45-13:00 By DLI:
13:00-13:15 Discussion
13:15-13:45 Lunch Break, Poster Viewing and Visit Exhibition
13:45-14:45 Industry-supported Lunch Symposium
14:45-15:00 Short Break
15:00-16:30 Session 4
Controversy: Is there a future for CAR-T cell therapy in T-All?
Moderator:
15:00-15:15 Yes: He Huang, China
15:15-15:30 No: Sebastian Giebel, Poland
Controversy: Are we ready for CAR-T in first-line therapy for MM?
Moderator: Nico Gagelmann, Germany
15:30-15:45 Yes: Maximilian Merz, Germany
15:45-16:00 No:
16:00-16:30 Panel discussion: All session faculty
16:30-17:00 Coffee Break, Poster Viewing and Visit Exhibition
17:00-18:30 Session 5
Controversy: Does MRD before allo impact the outcome for MDS?
Moderator:
17:00-17:15 Yes: Carmelo Gurnari, Italy
17:15-17:30 No: Arjan van de Loosdrecht, Netherlands
Controversy: Is venetoclax the new partner for 5-Aza in MDS?
Moderator: Arjan van de Loosdrecht, Netherlands
17:30-17:45 Yes: Valeria Santini, Italy
17:45-18:00 No: Moshe Mittelman, Israel
18:00-18:30 Panel discussion: All session faculty
Saturday, September 27
08:30-10:00 Session 6
Controversy: Is there a future for immunotherapy in AML outside allogeneic SCT?
Moderator: Charles Craddock, UK
08:30-08:45 Yes:
08:45-09:00 No:
Controversy: Is there a future for academic CARs?
Moderator: Valentín Ortíz-Maldonado, Spain
09:00-09:15 Yes: Arnon Nagler, Israel
09:15-09:30 No:
09:30-10:00 Panel discussion: All session faculty
10:00-10:20 Coffee Break, Poster Viewing and Visit Exhibition
10:20-11:20 Industry-supported Symposium
11:20-11:30 Technical Break
11:30-13:00 Session 7
Controversy: Is PTCy or ATG-based prophylaxis the better haplo approach in AML?
Moderator: Nicolaus Kröger, Germany
11:30-11:45 ATG/ATLG: Xiaojun Huang, China
11:45-12:00 PTCy: Leo Luznik, USA
Controversy: Does HLA matter in HSCT with PTCy?
Moderator: Arnon Nagler, Israel
12:00-12:15 Yes: Katharina Fleischhauer, Germany
12:15-12:30 No: Fabio Ciceri Italy
12:30-13:00 Panel discussion: All session faculty
13:00-13:30 Lunch Break, Poster Viewing and Visit Exhibition
13:30-14:30 Industry-supported Lunch Symposium
14:30-14:40 Technical Break
14:40-16:10 Session 8
Controversy: Splenectomy vs spleen irradiation in JAKi resistant MPN patients prior to alloSCT
Moderator: Donal McLornan, UK
14:40-14:55 Pro splenectomy: Nicola Polverelli, Italy
14:55-15:10 Pro spleen irradiation: Nico Gagelmann, Germany
Controversy: Does cord blood provide a stronger GVL effect than MUD?
Moderator: Robert Soiffer, USA
15:10-15:25 Yes: Robert Wynn, UK
15:25-15:40
15:40-16:10 Panel discussion: All session faculty
16:10-16:20 Short Break
16:20-17:50 Session 9
Controversy: Can modulation of microbiome by diet prevent or treat GvHD?
Moderator: Ernst Holler, Germany
16:20-16:35 Yes: Marcel van den Brink, USA
16:35-16:50 No: Hendrik Poeck, Germany
Controversy: Is fecal transplant the future treatment of SR-GvHD?
Moderator: Marcel van den Brink, USA
16:50-17:05 Yes: Ernst Holler, Germany
17:05-17:20 No: Pavan Reddy, USA
17:20-17:50 Panel discussion: All session faculty
17:50-18:10 Coffee Break, Poster Viewing and Visit Exhibition
18:10-19:30 Session 10
Controversy: Is there a role for combining JAKi with other agents in acute and chronic GvHD?
Moderator: Francesca Bonifazi, Italy
18:10-18:25 Yes:
18:25-18:40 No: Olaf Penack, Germanyaaa
Controversy: Are MAGIC criteria and biomarker the standard for classifying and treating acute GvHD?
Moderator: Ibrahim Yakoub-Agha, France
18:40-18:55 Yes: James Ferrara, USA
18:55-19:10 No: Amin Alousi, USA
19:10-19:30 Panel discussion: All session faculty
19:30 Poster Walk and Awards Session
(Poster Area)
Sunday, September 28
09:00-10:30 Session 11
Controversy: Can modern technology (e.g. AI) of large registries replace projective phase III studies?
Moderator: Nicolaus Kröger, Germany
09:00-09:15 Yes: Marcelo Pasquini, USA
09:15-09:30 No: Charles Craddock, UK
Controversy: Can we expect CAR-T cells to treat GvHD?
Moderator: Marcelo Pasquini, USA
09:30-09:45 Yes: Chiara Bonini, Italy
09:45-10:00 No: Bruce Blazar, USA
10:00-10:30 Panel discussion: All session faculty
10:30-11:00 Coffee Break
11:00-12:30 Session 12
Controversy: CAR-T vs BITE in autoimmune disease
Moderator: Raffaella Greco, Italy
11:00-11:15 Pro CAR:
11:15-11:30 Pro BITE: Tobias Alexander, Germany
Controversy: CAR-T vs BITE in advanced follicular lymphoma
Moderator:
11:30-11:45 Pro CAR:
11:45-12:00 Pro BITE: Anna Sureda, Spain
12:00-12:30 Panel discussion: All session faculty
12:30 Closing Remarks
Congress Co-Chairs